CLAIM : A method of reducing intraocular pressure (IOP) in a subject suffering from a disorder associated with intraocular pressure (IOP), the method comprising administering to the subject a GLP-1 receptor agonist, or a pharmaceutically acceptable salt thereof.
Note that this is for intraocular pressure and not intercranial pressure ..... Also note that Invex received its written feedback from the FDA on its trial design on 15th June 2021 where the FDA suggests that want a visual endpoint for IIH trial, also note that Dr. Meghan Baldwin (who knows a thing or two about the eyes - CEO of Opthea) joined the board on 16th June 2021 and that this patent application was filled on 17th September 2021.
This would suggest to me they feel if they are going to have to go for a visual endpoint in the US they might be looking to make a broader label claim than just IIH and also include certain glaucomas.
IXC Price at posting:
42.5¢ Sentiment: Buy Disclosure: Held
